Table 3.
Risk of myocardial infarction, ischemic stroke, and all-cause death in patients with diabetes and their matched general population comparison cohort
| Patients | Events | 10-year cumulative incidencea (95% CI) | Risk differencea (95% CI) |
Unadjusted HR (95% CI) | Adjusted HRb (95% CI) | Adjusted HRc (95% CI) | |
|---|---|---|---|---|---|---|---|
| Myocardial infarction | |||||||
| General population | 28,670 | 595 | 2.9% (2.7–3.1) | Reference | Reference | Reference | Reference |
| Diabetes patients | 5734 | 134 | 3.2% (2.7–3.8) | 0.3% (-0.3–0.9) | 1.26 (1.04–1.52) | 1.07 (0.84–1.36) | 0.93 (0.72–1.20) |
| Ischemic stroke | |||||||
| General population | 28,670 | 456 | 2.2% (2.0–2.4) | Reference | Reference | Reference | Reference |
| Diabetes patients | 5734 | 230 | 5.2% (4.5–5.9) | 3.0% (2.3–3.7) | 2.96 (2.51–3.50) | 2.04 (1.65–2.52) | 1.87 (1.47–2.38) |
| Death | |||||||
| General population | 28,670 | 3659 | 17.8% (17.2–18.3) | Reference | Reference | Reference | Reference |
| Diabetes patients | 5734 | 1228 | 29.6% (28.1–31.1) | 11.8% (10.2–13.4) | 1.88 (1.76–2.01) | 1.58 (1.45–1.72) | 1.24 (1.13–1.36) |
CAG coronary angiography, CI confidence interval, CIP cumulative incidence proportion, HR hazard ratio
aLimited to the 75th percentile of follow-up (10 years). In myocardial infarction and ischemic stroke, accounting for the competing risk of death
bAdjusted for myocardial infarction within 30 days of angiography, statin treatment, oral anticoagulant treatment, and antiplatelet treatment
cAdjusted for peripheral artery disease, hypertension, chronic obstructive pulmonary disease, myocardial infarction within 30 days of angiography, statin treatment, oral anticoagulant treatment, and antiplatelet treatment. In case of ischemic stroke and death, additionally adjusted for congestive heart failure, previous ischemic stroke/TIA, and atrial fibrillation